An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
The outcome of pancreatic cancer is extremely poor. NCCN guidelines recommend FOLFIRINOX or
modified-FOLFIRINOX as the first-line chemotherapeutic regimen, but the response rate is
unacceptably low. PD-1 blockade has been developed to a new class of cancer immunotherapy
that could restore an adequate immunosurveillance against the neoplasm and enhance
T-cell-mediated anticancer immune responses. Manganese has been confirmed to activate
antigen-presenting cells and function as mucosal immunoadjuvants in pre-clinical studies.
This one-arm, phase I/II study is designed to assess the safety and efficacy of Manganese
primed combined therapy of anti-PD-1 antibody and chemotherapy.